Comparison · NCT02969655-sae
Daprodustat vs Darbepoetin Alfa: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Daprodustat vs Darbepoetin Alfa: serious adverse events. Trial comparisons, record NCT02969655-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02969655-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.154 | 0.103 | 0.225 | wilson | |
| Risk in group 2 | 0.274 | 0.206 | 0.355 | wilson | |
| Risk difference, group 1 minus group 2 | -0.12 | -0.215 | -0.0218 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.563 | 0.349 | 0.91 | log | |
| Odds ratio, group 1 over group 2 | 0.484 | 0.266 | 0.881 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Daprodustat than on Darbepoetin Alfa | 8.36 | 4.65 | 45.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Daprodustat | Participants received oral daprodustat tablets (1, 2, 4, 6, 8, 12, 18 and 24 milligrams \[mg\] as recommended) once daily and intravenous (IV) darbepoetin alfa placebo injection (0.5 milliliter prefilled syringes containing no darbepoetin alfa) once weekly for 52 weeks. | 21 | 136 | EG000 |
| Group 2 | Darbepoetin Alfa | Participant received IV darbepoetin alfa injection (10,15,20,30,40 and 60 micrograms \[ug\] as recommended) once weekly and oral daprodustat placebo tablets (small and large tablets containing no daprodustat) once daily for 52 weeks. | 37 | 135 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events and serious adverse events were collected from the start of study treatment until the follow-up contact (Day 1 up to Follow-up Visit [Week 54])
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
- NCT number
- NCT02969655
- Phases
- PHASE3
- Conditions
- Anaemia
- Interventions
- Daprodustat small, Daprodustat small placebo, Daprodustat large, Daprodustat large placebo, Darbepoetin alfa, Darbepoetin alfa placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2019-11-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02969655?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02969655-sae